Skip to content
BiologicalX

Dosage guide

Clomiphene dosage

Clomiphene dosing: typical range, frequency, half-life, onset, routes. Evidence-tiered.

At a glance

Typical dose
25mg
Half-life
168hr
Frequency
5-day pulse cycle days 5 to 9 (women); daily or every other day (men, off-label)
Routes
oral

Protocol

  1. 1

    Measure the dose

    Typical Clomiphene dose is 25 mg. Use a weight-based calculator for individual adjustments.

    Open tool →
  2. 2

    Set the frequency

    Administer 5-day pulse cycle days 5 to 9 (women); daily or every other day (men, off-label). Half-life of 168 hours anchors the dosing interval.

    Open tool →
  3. 3

    Cycle if needed

    Female protocol uses 5-day pulse per cycle; male off-label use is continuous, sometimes with planned washouts

    Open tool →
  4. 4

    Monitor for side effects

    Watch for: hot flushes; mood changes; abdominal discomfort; breast tenderness. Stop or reduce dose if tolerability breaks down.

Why this dose

Selective estrogen receptor modulator that antagonizes estrogen at the hypothalamus and pituitary, increasing GnRH and gonadotropin output, which drives gonadal steroidogenesis.

The typical 25 mg dose is the figure most commonly used in published protocols for Clomiphene. Treat the label as a starting point: body weight, training status, sleep, diet, and concurrent medications all shift the effective dose-response curve in real users.

How to administer

Clomiphene is administered via the oral route. Oral dosing is straightforward: take with water, with or without food unless specifically noted.

Onset of action runs around 6 hours after administration. Peak effect lands near 7 hours post-dose. Plan the administration window so that peak effect lines up with whatever outcome you are dosing for, whether that is training, sleep, or symptom coverage.

Half-life note: Racemic clomiphene biphasic; enclomiphene ~10 hours, zuclomiphene 2 to 3 weeks. Enclomiphene-only formulations have cleaner PK.

Cycling and tolerance

Female protocol uses 5-day pulse per cycle; male off-label use is continuous, sometimes with planned washouts

Effects to expect at typical dose

  • SERM that blocks estrogen-receptor negative feedback at the hypothalamus, raising LH and FSH
  • FDA approved 1967 for ovulation induction in anovulatory women at 50 to 100 mg cycle days 5 to 9
  • Off-label in men at 12.5 to 25 mg daily raises endogenous testosterone while preserving fertility
  • Enclomiphene (trans-isomer) is preferred for male use; cleaner PK and less estrogenic side effect burden
  • Visual disturbances occur in ~1 to 2% of users; persistent symptoms warrant immediate cessation
  • Letrozole has displaced clomiphene as first-line ovulation induction in PCOS (Legro 2014)

Best-graded outcomes

  • A Ovulation induction in anovulatory women : 70 to 80% ovulation rate (Anovulatory infertility (mixed etiologies)).
  • A Endogenous testosterone elevation in men : 200 to 500 ng/dL increase typical (Secondary hypogonadism, 12.5 to 25 mg).
  • A Live-birth rate in PCOS : Lower than letrozole (PPCOS-II) (PCOS, head-to-head with letrozole).

Side effects and interactions

Common side effects

  • hot flushes
  • mood changes
  • abdominal discomfort
  • breast tenderness
  • visual disturbances (rare)

Notable interactions

  • tamoxifen (moderate): competing SERM activity; not used together
  • ospemifene (moderate): competing SERM activity
  • TRT (exogenous testosterone) (moderate): TRT suppresses HPT axis that clomiphene targets; do not combine
  • anastrozole (minor): additive estrogen reduction; sometimes combined in male protocols

Lists above cover commonly reported and well-characterized items. They are not exhaustive: review the full Clomiphene profile and discuss with a clinician familiar with your medication list before starting, particularly if you are on prescription therapy or have a chronic condition.

Regulatory snapshot

WADA status
banned
DEA / Rx
Rx only (not a controlled substance)
Pregnancy
Category X; contraindicated in pregnancy
Legal status
Prescription only (FDA approved for ovulation induction; off-label in men)

Do not use if

  • pregnancy
  • active liver disease
  • ovarian cysts (not PCOS-related)
  • uncontrolled thyroid or adrenal disorder
  • abnormal uterine bleeding of undetermined origin
  • hormone-sensitive cancer

Related calculators

Related research